If you have hereditary amyloidosis and are experiencing nerve pain, tingling, or muscle weakness, you may qualify for the ATTRibute-PN clinical research study.
Polyneuropathy associated with hereditary amyloidosis (ATTR-PN) is a rare condition that is passed down through families. The ATTRibute-PN study is researching the safety and effectiveness of the study drug in people diagnosed with this condition.